lenercept

Lenercept (Ro 45-2081) is a recombinant fusion protein biologic consisting of two molecules of the human 55-kDa tumor necrosis factor (TNF) receptor (p55) linked to the Fc portion of human IgG1. Developed by Roche, it acts as a soluble TNF-alpha inhibitor, designed to neutralize the pro-inflammatory effects of TNF-alpha. It was investigated for the treatment of chronic inflammatory conditions such as rheumatoid arthritis and multiple sclerosis, as well as for severe sepsis and septic shock. However, development was discontinued after clinical trials failed to demonstrate efficacy; notably, in multiple sclerosis, lenercept was found to increase the frequency and severity of disease exacerbations. Additionally, the formation of non-neutralizing anti-drug antibodies led to rapid clearance from the systemic circulation.

Other names

sTNFR-IgG p55p55-IgGp-55-IgGp 55-IgGtumor necrosis factor receptor p55-Fc IgG1 fusion protein